Can Repatha (evolocumab) be taken with other medications?

From the Guidelines

Repatha (evolocumab) can be taken with most medications, but it is crucial to consult with your healthcare provider before combining it with any other drugs, especially those that may interact with its mechanism of action or increase the risk of side effects. According to the 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk 1, Repatha is a PCSK9 inhibitor used to lower LDL cholesterol and doesn't have many significant drug interactions. However, your question appears incomplete as it ends with "o" - if you're asking about a specific medication that begins with "o" like omeprazole, oxycodone, or others, the answer may vary.

When taking Repatha, which is typically administered as a subcutaneous injection every 2 or 4 weeks depending on the dose (140 mg or 420 mg), always inform your doctor about all medications you're taking, including prescription drugs, over-the-counter medicines, vitamins, and supplements. This helps prevent potential interactions. Repatha works by blocking the PCSK9 protein, which allows more LDL receptors to remain available on liver cells to remove LDL cholesterol from the blood, making it generally compatible with most other medication types.

Some key points to consider when taking Repatha with other medications include:

• Informing your doctor about all medications you're taking
• Being aware of potential interactions with other cholesterol-lowering medications
• Monitoring your LDL cholesterol levels and adjusting your treatment plan as needed
• Reporting any side effects or concerns to your healthcare provider

It's essential to prioritize your health and safety by consulting with your healthcare provider before combining Repatha with any other medications, especially if you're taking medications that may interact with Repatha or increase the risk of side effects, as reported in the study 1.

From the FDA Drug Label

If your healthcare provider has prescribed REPATHA along with other cholesterol-lowering medicines for you or your child, follow instructions from your healthcare provider. The FDA drug label does not answer the question about taking Repatha with a specific medication, only that it can be taken with other cholesterol-lowering medicines as prescribed by a healthcare provider.

• Key Point: The label does not provide information on taking Repatha with a specific medication "o". 2

From the Research

Repatha (Evolocumab) Administration and Compatibility

• Repatha (evolocumab) is a monoclonal antibody administered subcutaneously at a dosage of 140 mg every 2 weeks or 420 mg once monthly 3.
• The efficacy of evolocumab was maintained in the longer term, and it was well tolerated when added to statin therapy, in statin-intolerant patients, as monotherapy, and in patients with heterozygous familial hypercholesterolemia who were receiving statins with or without other lipid-lowering drugs 3.
• Evolocumab reduced low-density lipoprotein cholesterol (LDL-C) in 12-week trials in statin-intolerant patients, and the persistence of efficacy during longer-term treatment was also observed 4.

Interaction with Other Medications

• Evolocumab can be taken with statins, and the combination has been shown to be effective in reducing LDL-C levels and cardiovascular events 5, 6.
• The addition of evolocumab to a statin has been shown to confer a significant reduction in major cardiovascular events, including a 20% reduction in the composite of cardiovascular death, myocardial infarction, or stroke 5.
• Evolocumab has also been shown to be effective in reducing cardiovascular events in patients with stable atherosclerotic cardiovascular disease, regardless of whether the baseline LDL-C was less than 70 or at least 70 mg/dL, and whether the background statin was of maximal or submaximal potency 6.

Safety and Tolerability

• Evolocumab has been shown to be well tolerated, with no major safety concerns identified 4, 6.
• The most common adverse events associated with evolocumab were local injection site reactions 5.
• The combination of statin and evolocumab has been shown to produce favorable changes in coronary atherosclerosis, consistent with stabilization and regression 7.